News Daily News Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care Shelley Wood May 27, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs Todd Neale May 18, 2021
News Conference News ACC 2021 PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI L.A. McKeown May 15, 2021
News Daily News Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA Michael O'Riordan April 26, 2021
News Daily News Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF Michael O'Riordan April 15, 2021
News Daily News New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF Todd Neale February 16, 2021
News Daily News Did Regional Differences Muddy Results in COMMANDER-HF? L.A. McKeown February 04, 2021
News Daily News FDA Approves Vericiguat for High-risk Patients With HF Michael O'Riordan January 20, 2021
News Daily News ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care L.A. McKeown January 11, 2021
News Conference News AHA 2020 Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD L.A. McKeown November 18, 2020
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Conference News AHA 2020 Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF Todd Neale November 16, 2020
News Conference News AHA 2020 Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF Todd Neale November 13, 2020
News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Conference News ESC 2020 PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF Todd Neale August 30, 2020